Related Experiment Video
Updated: Jan 5, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
[Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors]
Xiaoyan Si1, Chunxia He2, Li Zhang3
1Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Beijing 100730, China.
Abstract:
Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic AEs, including Stevens-Johnson syndrome and toxic epidermal necrolysis, are rare. In this review, we summarized guidelines of management of immunotherapy-related toxicities and case reports, and proposed treatment recommendation.
Related Concept Videos
Tumor Immunotherapy
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Therapeutic Drug Monitoring: Affecting Factors
Nephrotic Syndrome III : Nursing Management

